ACADIA Pharmaceuticals Inc. Long-term assets (Other)

Long-term assets (Other) of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long-term assets (Other) growth rates and interactive chart. All other non-current assets that do not fit the categories above.


Highlights and Quick Summary

  • Long-term assets (Other) for the quarter ending March 30, 2021 was $1.81 Million (a 379.63% increase compared to previous quarter)
  • Year-over-year quarterly Long-term assets (Other) increased by 241.43%
  • Annual Long-term assets (Other) for 2020 was $378 Thousand (a -32.14% decrease from previous year)
  • Annual Long-term assets (Other) for 2019 was $557 Thousand (a -70.67% decrease from previous year)
  • Annual Long-term assets (Other) for 2018 was $1.9 Million (a 436.44% increase from previous year)
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long-term assets (Other) of ACADIA Pharmaceuticals Inc.

Most recent Long-term assets (Other)of ACAD including historical data for past 10 years.

Interactive Chart of Long-term assets (Other) of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Long-term assets (Other) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $1.81
2020 $0.38 $0.55 $0.53 $0.54 $0.38
2019 $7.64 $7.09 $6.38 $6.35 $0.56
2018 $6.73 $4.54 $6.3 $3.15 $1.9
2017 $2.83 $2.84 $3.0 $3.14 $0.35
2016 $3.16 $3.35 $3.49 $1.62 $0.79
2015 $0.7 $0.41 $0.33 $0.28 $0.7
2014 $0.29 $0.18 $0.11 $0.14 $0.29
2013 $0.18 $0.12 $0.06 $0.18
2012 $0.0 $0.01 $0.01
2011 $0.01 $0.08 $0.09 $0.1 $0.01
2010 $0.12 $0.14 $0.15 $0.12

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.